Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
Analytic and Translational Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.
Genet Med. 2019 Apr;21(4):798-812. doi: 10.1038/s41436-018-0408-7. Epub 2019 Jan 18.
Identifying genes and variants contributing to rare disease phenotypes and Mendelian conditions informs biology and medicine, yet potential phenotypic consequences for variation of >75% of the ~20,000 annotated genes in the human genome are lacking. Technical advances to assess rare variation genome-wide, particularly exome sequencing (ES), enabled establishment in the United States of the National Institutes of Health (NIH)-supported Centers for Mendelian Genomics (CMGs) and have facilitated collaborative studies resulting in novel "disease gene" discoveries. Pedigree-based genomic studies and rare variant analyses in families with suspected Mendelian conditions have led to the elucidation of hundreds of novel disease genes and highlighted the impact of de novo mutational events, somatic variation underlying nononcologic traits, incompletely penetrant alleles, phenotypes with high locus heterogeneity, and multilocus pathogenic variation. Herein, we highlight CMG collaborative discoveries that have contributed to understanding both rare and common diseases and discuss opportunities for future discovery in single-locus Mendelian disorder genomics. Phenotypic annotation of all human genes; development of bioinformatic tools and analytic methods; exploration of non-Mendelian modes of inheritance including reduced penetrance, multilocus variation, and oligogenic inheritance; construction of allelic series at a locus; enhanced data sharing worldwide; and integration with clinical genomics are explored. Realizing the full contribution of rare disease research to functional annotation of the human genome, and further illuminating human biology and health, will lay the foundation for the Precision Medicine Initiative.
确定导致罕见疾病表型和孟德尔疾病的基因和变异,为生物学和医学提供了信息,但人类基因组中约 20000 个注释基因中超过 75%的变异的潜在表型后果尚不清楚。评估罕见变异的技术进步,特别是外显子组测序(ES),使美国国立卫生研究院(NIH)支持的孟德尔基因组学中心(CMGs)得以建立,并促进了合作研究,从而发现了新的“疾病基因”。基于家系的基因组研究和疑似孟德尔疾病家系中的罕见变异分析,阐明了数百个新的疾病基因,并强调了新生突变事件、非肿瘤特征的体细胞变异、不完全外显等位基因、高基因座异质性表型和多基因致病性变异的影响。在此,我们重点介绍了 CMG 合作发现,这些发现有助于理解罕见病和常见病,并讨论了单基因孟德尔疾病基因组学未来发现的机会。所有人类基因的表型注释;开发生物信息学工具和分析方法;探索非孟德尔遗传方式,包括外显率降低、多基因变异和寡基因遗传;构建基因座上的等位基因系列;在全球范围内加强数据共享;以及与临床基因组学的整合。实现罕见病研究对人类基因组功能注释的全部贡献,进一步阐明人类生物学和健康,将为精准医学倡议奠定基础。